EGFR and non-small cell lung carcinoma: Approximately 60% of East Asian non-small-cell lung cancers (NSCLC), 30% of breast cancers, and 40% of glioblastoma multiforme (GBM) either overexpress or bear activating mutations/in-frame deletions in EGFR or its family members [8,22,23,24].